Yuanlin Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yuanlin Sun has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Xueyuan Cao
Department of Gastric and Colorectal Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, China
2 shared publications Yingnan Cui
Department of Gastric and Colorectal Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, China
2 shared publicationsBin Liu
Department of Gastrointestinal Surgery
1 shared publicationBing Liu
Department of Gastrointestinal Surgery Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences Jinan China
1 shared publicationBo Bi
Department of Gastrointestinal Surgery Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences Jinan China
1 shared publication- Dong Sun
Department of Gastrointestinal Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China. dsun@.sdfmu.edu.cn
1 shared publication
Latest Publications
- Open Access
- 6 May 2026
- Published by Wiley in Clinical and Translational Medicine
- Vol. 16 (5) , e70679
Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S‐1 for neoadjuvant therapy of locally advanced gastric cancer with HER2‐overexpressing: Preliminary results of a prospective, single‐arm, phase II study
Purpose: Perioperative treatment of gastric and gastroesophageal junction (G/GEJ) cancer is evolving towards multimodal strategies incorporating HER2‐targeted therapy, immunotherapy and chemotherapy. Disitamab vedotin (RC48), an HER2‐targeted antibody–drug conjugate, shows promising antitumour activity and potential synergy with immune checkpoint inhibitors. This study evaluated neoadjuvant RC48 combined with camrelizumab and S‐1 in resectable HER2‐overexpressing locally advanced G/GEJ adenocarcinoma. Methods: Patients with histologically confirmed HER2‐overexpressing (IHC 3+ or 2+) resectable G/GEJ cancer staged as cT3‐4aN1‐3M0 were enrolled in this prospective single‐arm phase II study. Patients received three 3‐weekly cycles of RC48, camrelizumab and S‐1 before surgery. Pathological complete response (pCR) was defined as the primary endpoint, whereas major pathological response (MPR), objective response rate (ORR), tumour downstaging, disease‐free survival (DFS), overall survival (OS) and safety were evaluated as secondary endpoints. Exploratory circulating tumour DNA (ctDNA) methylation profiling (PredicineEPIC) assessed molecular response dynamics and ERBB2 copy number variation. Results: From 18 September 2022 to 12 December 2024, 32 patients were enrolled; 24 proceeded to D2 resection. The ORR after neoadjuvant therapy was 80.0% (24/30). In the surgical cohort, pCR and MPR were achieved in 25.0% (6/24) and 45.8% (11/24) of patients, respectively, with an R0 resection rate of 100%. The median DFS and OS were not reached at the time of analysis. In the ctDNA substudy ( n = 14), methylation‐derived tumour fraction declined during therapy and ERBB2 plasma copy number gain aligned with tissue HER2 status. Treatment‐related adverse events of grade ≥3 were reported in 31.3% of patients. Conclusion: Neoadjuvant RC48 combined with camrelizumab and S‐1 showed potential antitumour activity with an acceptable safety profile in HER2‐overexpressing locally advanced resectable G/GEJ adenocarcinoma. Key points: Neoadjuvant RC48 plus camrelizumab and S‐1 showed encouraging pathological responses in HER2‐overexpressing gastric cancer. The regimen achieved a pCR rate of 25% and an MPR rate of 45.8%. The combination therapy demonstrated a manageable safety profile. Exploratory ctDNA methylation analysis suggested potential for dynamic response monitoring.
- 6 May 2026
- Published by Wiley in Clinical and Translational Medicine
- Vol. 16 (5) , e70679
Open AccessEfficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S‐1 for neoadjuvant therapy of locally advanced gastric cancer with HER2‐overexpressing: Preliminary results of a prospective, single‐arm, phase II study
Purpose: Perioperative treatment of gastric and gastroesophageal junction (G/GEJ) cancer is evolving towards multimodal strategies incorporating HER2‐targeted therapy, immunotherapy and chemotherapy. Disitamab vedotin (RC48), an HER2‐targeted antibody–drug conjugate, shows promising antitumour activity and potential synergy with immune checkpoint inhibitors. This study evaluated neoadjuvant RC48 combined with camrelizumab and S‐1 in resectable HER2‐overexpressing locally advanced G/GEJ adenocarcinoma. Methods: Patients with histologically confirmed HER2‐overexpressing (IHC 3+ or 2+) resectable G/GEJ cancer staged as cT3‐4aN1‐3M0 were enrolled in this prospective single‐arm phase II study. Patients received three 3‐weekly cycles of RC48, camrelizumab and S‐1 before surgery. Pathological complete response (pCR) was defined as the primary endpoint, whereas major pathological response (MPR), objective response rate (ORR), tumour downstaging, disease‐free survival (DFS), overall survival (OS) and safety were evaluated as secondary endpoints. Exploratory circulating tumour DNA (ctDNA) methylation profiling (PredicineEPIC) assessed molecular response dynamics and ERBB2 copy number variation. Results: From 18 September 2022 to 12 December 2024, 32 patients were enrolled; 24 proceeded to D2 resection. The ORR after neoadjuvant therapy was 80.0% (24/30). In the surgical cohort, pCR and MPR were achieved in 25.0% (6/24) and 45.8% (11/24) of patients, respectively, with an R0 resection rate of 100%. The median DFS and OS were not reached at the time of analysis. In the ctDNA substudy ( n = 14), methylation‐derived tumour fraction declined during therapy and ERBB2 plasma copy number gain aligned with tissue HER2 status. Treatment‐related adverse events of grade ≥3 were reported in 31.3% of patients. Conclusion: Neoadjuvant RC48 combined with camrelizumab and S‐1 showed potential antitumour activity with an acceptable safety profile in HER2‐overexpressing locally advanced resectable G/GEJ adenocarcinoma. Key points: Neoadjuvant RC48 plus camrelizumab and S‐1 showed encouraging pathological responses in HER2‐overexpressing gastric cancer. The regimen achieved a pCR rate of 25% and an MPR rate of 45.8%. The combination therapy demonstrated a manageable safety profile. Exploratory ctDNA methylation analysis suggested potential for dynamic response monitoring.
- Open Access
- 1 November 2023
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 11, 1275543
The crosstalk among the physical tumor microenvironment and the effects of glucose deprivation on tumors in the past decade
The occurrence and progression of tumors are inseparable from glucose metabolism. With the development of tumors, the volume increases gradually and the nutritional supply of tumors cannot be fully guaranteed. The tumor microenvironment changes and glucose deficiency becomes the common stress environment of tumors. Here, we discuss the mutual influences between glucose deprivation and other features of the tumor microenvironment, such as hypoxia, immune escape, low pH, and oxidative stress. In the face of a series of stress responses brought by glucose deficiency, different types of tumors have different coping mechanisms. We summarize the tumor studies on glucose deficiency in the last decade and review the genes and pathways that determine the fate of tumors under harsh conditions. It turns out that most of these genes help tumor cells survive in glucose-deprivation conditions. The development of related inhibitors may bring new opportunities for the treatment of tumors.
- 1 November 2023
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 11, 1275543
Open AccessThe crosstalk among the physical tumor microenvironment and the effects of glucose deprivation on tumors in the past decade
The occurrence and progression of tumors are inseparable from glucose metabolism. With the development of tumors, the volume increases gradually and the nutritional supply of tumors cannot be fully guaranteed. The tumor microenvironment changes and glucose deficiency becomes the common stress environment of tumors. Here, we discuss the mutual influences between glucose deprivation and other features of the tumor microenvironment, such as hypoxia, immune escape, low pH, and oxidative stress. In the face of a series of stress responses brought by glucose deficiency, different types of tumors have different coping mechanisms. We summarize the tumor studies on glucose deficiency in the last decade and review the genes and pathways that determine the fate of tumors under harsh conditions. It turns out that most of these genes help tumor cells survive in glucose-deprivation conditions. The development of related inhibitors may bring new opportunities for the treatment of tumors.
- Open Access
- 21 September 2022
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 15, 1011-1020
PTEN Expression Was Significantly Associated with PD-L1 Score but Not with EBV Infection in Gastric Cancer
Dove Press is a member of the Open Access Initiative, specializing in peer reviewed Medical Journals. View articlesor submit your research for publishing
- 21 September 2022
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 15, 1011-1020
Open AccessPTEN Expression Was Significantly Associated with PD-L1 Score but Not with EBV Infection in Gastric Cancer
Dove Press is a member of the Open Access Initiative, specializing in peer reviewed Medical Journals. View articlesor submit your research for publishing
- Open Access
- 20 January 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 5614915
The Prognostic and Molecular Landscape of Autophagy‐Related Long Noncoding RNA in Colorectal Cancer
Current evidence suggests that autophagy is closely correlated with the pathogenesis and development of malignant tumors. This study is aimed at assessing the potential prognostic significance of autophagy‐related long noncoding RNA (ARlncRNA) in colorectal cancer (CRC). 3145 ARlncRNAs were obtained from autophagy‐related genes (ARGs) by Pearson correlation analysis, and we established a competing endogenous RNA (ceRNA) network mediated by ARlncRNAs. A novel six‐ARlncRNA prognostic signature was constructed based on TCGA samples used as the training group. Kaplan–Meier survival analysis and independent prognosis analysis were performed on the internal (training and test groups) and external validations (GEO datasets) to assess the accuracy and clinical practicability. Moreover, the nomogram combining the two independent prognostic factors (age and ARlncRNA‐risk score (ARlncRNA‐RS)) intuitively displayed overall survival. Gene set enrichment analysis (GSEA) conducted on the prognostic signature revealed that the gene set of the high‐risk group was significantly enriched in the hallmark gene set “hypoxia” and the gene set of the low‐risk group was enriched in KEGG pathways, including “peroxisome,” “the citrate cycle (TCA cycle),” and “other glycan degradation.” Assessment of antineoplastic therapy susceptibility and microsatellite instability (MSI) analysis were performed on CRC samples based on the prognostic signature. Moreover, Spearman correlation analysis was conducted on the expression of six ARlncRNAs of the prognostic signature and cancer stem cell (CSC) index as well as the tumor microenvironment (TME). In conclusion, this study established a six‐ARlncRNA prognostic signature, which yielded favorable prognostic significance and demonstrated the correlation between ARlncRNAs and CRC progression.
- 20 January 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 5614915
Open AccessThe Prognostic and Molecular Landscape of Autophagy‐Related Long Noncoding RNA in Colorectal Cancer
Current evidence suggests that autophagy is closely correlated with the pathogenesis and development of malignant tumors. This study is aimed at assessing the potential prognostic significance of autophagy‐related long noncoding RNA (ARlncRNA) in colorectal cancer (CRC). 3145 ARlncRNAs were obtained from autophagy‐related genes (ARGs) by Pearson correlation analysis, and we established a competing endogenous RNA (ceRNA) network mediated by ARlncRNAs. A novel six‐ARlncRNA prognostic signature was constructed based on TCGA samples used as the training group. Kaplan–Meier survival analysis and independent prognosis analysis were performed on the internal (training and test groups) and external validations (GEO datasets) to assess the accuracy and clinical practicability. Moreover, the nomogram combining the two independent prognostic factors (age and ARlncRNA‐risk score (ARlncRNA‐RS)) intuitively displayed overall survival. Gene set enrichment analysis (GSEA) conducted on the prognostic signature revealed that the gene set of the high‐risk group was significantly enriched in the hallmark gene set “hypoxia” and the gene set of the low‐risk group was enriched in KEGG pathways, including “peroxisome,” “the citrate cycle (TCA cycle),” and “other glycan degradation.” Assessment of antineoplastic therapy susceptibility and microsatellite instability (MSI) analysis were performed on CRC samples based on the prognostic signature. Moreover, Spearman correlation analysis was conducted on the expression of six ARlncRNAs of the prognostic signature and cancer stem cell (CSC) index as well as the tumor microenvironment (TME). In conclusion, this study established a six‐ARlncRNA prognostic signature, which yielded favorable prognostic significance and demonstrated the correlation between ARlncRNAs and CRC progression.